# Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation

> **NCT03443791** · NA · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 200 (actual)

## Conditions studied

- Cmv Congenital
- CMV Viremia

## Interventions

- **DIAGNOSTIC_TEST:** Women Enrolled
- **DIAGNOSTIC_TEST:** Newborns of Female Study Participants

## Key facts

- **NCT ID:** NCT03443791
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443791, "Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03443791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*